These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26916158)

  • 1. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
    Hannan JP
    Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
    Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
    J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
    Young KA; Chen XS; Holers VM; Hannan JP
    J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
    Asokan R; Hua J; Young KA; Gould HJ; Hannan JP; Kraus DM; Szakonyi G; Grundy GJ; Chen XS; Crow MK; Holers VM
    J Immunol; 2006 Jul; 177(1):383-94. PubMed ID: 16785534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
    J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
    J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
    Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
    J Biol Chem; 2010 Aug; 285(35):27251-27258. PubMed ID: 20558730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
    Molina H; Perkins SJ; Guthridge J; Gorka J; Kinoshita T; Holers VM
    J Immunol; 1995 May; 154(10):5426-35. PubMed ID: 7730644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions.
    Gilbert HE; Asokan R; Holers VM; Perkins SJ
    J Mol Biol; 2006 Oct; 362(5):1132-47. PubMed ID: 16950392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
    Hannan JP; Young KA; Guthridge JM; Asokan R; Szakonyi G; Chen XS; Holers VM
    J Mol Biol; 2005 Feb; 346(3):845-58. PubMed ID: 15713467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of complement receptor 2 in complex with its C3d ligand.
    Szakonyi G; Guthridge JM; Li D; Young K; Holers VM; Chen XS
    Science; 2001 Jun; 292(5522):1725-8. PubMed ID: 11387479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
    Carel JC; Myones BL; Frazier B; Holers VM
    J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.
    Prodinger WM
    Immunol Res; 1999; 20(3):187-94. PubMed ID: 10741859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.
    Henchoz-Lecoanet S; Jeannin P; Aubry JP; Graber P; Bradshaw CG; Pochon S; Bonnefoy JY
    Immunology; 1996 May; 88(1):35-9. PubMed ID: 8707347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
    Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
    J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
    Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
    J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.